Introduction
Cardiovascular diseases, including severe cardiac valve disorders, are the leading global cause of disability and death, causing more than 17.5 million deaths a year (Ref. 1); the prevalence of valvular heart disease in the United States of America (USA) is estimated at more than 5 million people. Moreover, aortic valve disease, which affects 2.5% of the US adult population to some extent, is responsible for more than 25,000 deaths each year (Ref. 2). Also, 3% of sudden deaths in the European Union (EU) are caused by cardiac valve defects. Over the preceding decades valvular heart diseases were not considered a major public health problem. However, Nkomo et al. (Ref. 3) demonstrated in 2006 that the high prevalence of these disorders, together with their boost with ageing, indicated the burden of these conditions would only likely increase in the future.
The advent of organ transplantation has brought about the greatest progress in cardiac valve disease treatment so far, however, the number of patients that need heart valve replacements is rising by an average of 5% per year (Ref. 4) . This number is likely to triple over the next five decades due to the continuously increasing aging of the population in developed countries (Ref. 5) . According to the Global Alliance in Transplantation, the USA is currently the world's leader in heart valve replacements, reaching 95,000 cases per year (Ref. 6 ) but this is not an exception. By the year 2020, 20.2% of EU population will be older than 65. The growing pool of older people living in the area with age related heart valve disorders will continue to boost demand for heart valve repair and replacement procedures. These medical procedures, Even more dramatic is the case of children and young adults where cardiac valve defects represent approximately 30% of all congenital cardiovascular malformations. Only in the USA, the incidence is estimated at 1-2/1,000 births, and globally is around 8/1,000 births (Ref. 8, 9) . Congenital heart defects are relatively common and serious malformations having significant impact on morbidity, mortality, and healthcare costs. Homografts are used for their long durability in these patients but they show a higher immunological response compared to adults (Ref.
10). Moreover post-surgical calcification and the ultimate destruction of the valve replacement always occur more frequently in children and young adults than in old patients. In addition, the durability of the homografts in this case is also limited because of their inability to grow with concomitant growth of child organism. Consequently, the need for reoperation is higher in younger patients (O'Brien, 2001 #898;Rajani, 1998 #897}. Further efforts focused on paediatric recipients of cardiac valves are required.
Although organ replacement saves many lives the need for more donors, together with the collateral problems caused after transplantation, encourage the search for new alternatives (Ref. 11, 12) . Cardiac valve replacement is not an exception to the rule and several problems have to be solved: the administration of lifelong immunosuppressive drugs, poor durability and resulting short lifespan of the mechanical prostheses, structural degradation of the biological valve replacement, risk of rejection, and the risk of zoonosis from xenotransplants. Even with the significant innovations currently reached, a perfect valve substitute has still not yet been developed (Ref. 11), and approaches based on tissue engineering (TE) are now being considered for developing artificial heart valves (Ref. 13, 14) .
Tissue-engineered heart valves (TEHVs) have the potential to become the best solution for treating valvular heart diseases due to their nonthrombogenicity, decreased risk of infections and low structural deterioration over time (Ref. 13 ).There are two crucial challenges derived from three major components (cells, scaffolds and signalling molecules) in TE field; the former is the selection of potential candidate cell types and their related issues concerning ethics, safety, and effectiveness. The latter is the design of appropriate scaffolds that let for cell growth and differentiation as well as host tissue integration.
In this review we evaluate the current treatment strategies for valvular heart disease and their limitations with a view to provide valuable information in selecting the best approach for heart valve tissue engineering (HVTE), the challenges that HVTE faces today and the current status of the research in the field. This review focuses on the aortic valve due to the fact that aortic diseases have the poorest prognosis, even the higher incidence of mitral valve diseases in the population (Ref. 15 ). However, research on pulmonary valve is also taken into account since pulmonary autograft represents a proof of principle for clinical effectiveness of TEHVs (Ref. 16, 17) .
Understanding of heart valve biology

Substructural elements
Mammalian hearts comprise four heart valves: pulmonary, aortic, mitral, and tricuspid, whose primary function is to maintain a unidirectional blood flow during the cardiac cycle. We focus in the first two types, which are shown in Figure 1a and 1b, but especially our main interest is the aortic valve. Pulmonary and aortic valves, also called semilunar valves, are commonly affected by pathological processes, but with distinct mechanisms of failure (Ref. 18 ) that we will treat later. Both share similar structure containing three semicircular leaflets, or cusps, joined to a fibrous annulus called the root. According to Stradins et al. (Ref. 19) , aortic and pulmonary valve tissues have similar mechanical characteristics and composition, but exhibit slight differences in their layer density and thickness. The cross-sectional structure of the leaflets is divided into three layers, namely the ventricularis, spongiosa, and fibrosa (Ref. 12) whose structure and composition are detailed in the cross-sectional diagram in Figure 2 . These layers are dynamic tissues with complex structure mainly composed of valvular interstitial cells (VICs) and endothelial cells (VECs) combined with extracellular matrix (ECM). This make them capable of remodelling themselves in response to the changes generated by local forces (Ref. 20) .
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The semilunar valves also possess blood vessels. The majority of them are present in the proximal portion near the myocardium, with few found in the cusps, which are nourished by diffusion from the blood in the heart because of their thinner structure.
The creation of a functional TEHV requires profound knowledge of the healthy valve structure, the biological processes associated with their development, and also their functional features and requirements for their formation. The main components that comprised the aortic valve are described in the following subsections.
Valvular interstitial cells
Valvular interstitial cells, the most abundant cell type in heart valves, are a heterogeneous population embedded in their own ECM. 
Extracellular matrix
The ECM is considered to be the main responsible for the durability of heart valves. As shown in Figure 2 , its principal components are collagens type I and type III, elastin, glycosaminoglycans (GAGs), and proteoglycans (PGs). Collagens are fundamental for valve´s biomechanical functions, providing stiffness and elasticity; moreover, they have a strong influence on cell adhesion and migration (Ref. 38). Microscopically, the three layers that make up the valve have different ECM composition. For instance the thinnest layer, the ventricularis, is mainly composed of elastin which provides elasticity (Ref. 39), whereas the thickest layer, the fibrosa that is in charge of providing mechanical strength and load resistance to the valve, mainly contains collagen I and III (3:1) and 2% of collagen type IV (Ref. 33, 40).
The spongiosa layer, responsible for the compressible stiffness required for proper heart valve function, contains mainly GAGs and PGs. GAGs are largely responsible for the huge waterabsorbing capacity of this layer thanks to the high concentration of negative charges that they carry. Furthermore, GAGs are also required for hydration of the spongiosa layer and absorb compressive forces, reducing flexural deformation (Ref. 41). Given their nature, GAGs can also reduce the calcification process by chelating calcium ions. All of these features are important factors which go towards explaining the mechanical behaviour of heart valve tissues. In particular GAGs are crucial components that must be considered when creating TEHVs. For instance, after the process of decellularization with detergents, GAG loss was observed in valve tissues, compromising their structure and functions (Ref. 42).
Heart valve ECM is subjected to dynamic remodelling, which is induced by VICs. The quantity and quality of ECM essentially depends on the nature of the VICs (Ref. 33, 40 
Heart valve biomechanics and related illnesses
Mitral and aortic valves are in charge of pumping the blood, experiencing intense pressure, and supporting higher biomechanical stress than pulmonary and tricuspid. Therefore, they are more affected by pathologies and degenerative processes while alterations in pulmonary or tricuspid valves are less common and mainly related with genetic or foetal defects (Ref. 12). Valve pathologies are characterized within two functional groups: stenosis and regurgitation. Haemodinamically, the pulmonary valve flow profile is similar to that of the aortic, but the velocity magnitude is lower (Ref. 30). The slightly difference in the biomechanical and ultrastructural properties aforementioned in Section 2.1 strongly constraints the type of disease developed. Pathologies of the aortic valve can be triggered by inflammation or by degenerative valve disease, caused by aging coupled with rheumatic and infective endocarditis (Ref. 44). On the contrary, congenital stenosis is the most common pulmonary valve pathology, mainly caused by a defect during foetal development; this alteration is normally solved by surgery during infancy. Finally, mitral regurgitation, which can be caused by rheumatic fever, congenital abnormalities, ischemic heart disease or cardiomyopathies, is the most common functional abnormality of this valve.
Cardiac valve problems and
clinical strategies for their treatment: the importance of valve tissue banks.
As we mentioned above, different illnesses can compromise and damage the delicate structure of heart valves, triggering their alteration and causing the three main valve problems: regurgitation, stenosis and calcification. In the past the inflammation caused by rheumatic heart disease and endocarditis induced by bacterial infections were the root causes of valve alterations. Although these problems remain a major health roadblock in developing countries (Ref. 3) , valve dysfunctions in the industrialized world are almost always caused by degenerative diseases, mostly as a result of aging and congenital defects (Ref. 11). Several drugs can be used as short-term therapies to improve the health and condition of patients with severe valvular pathologies, however in most cases the best option for correcting the problem is to proceed with valve repair surgery and/or replacement. The choice of surgical procedure is adapted to the team's experience, the presence of an aneurysm, the characteristics of the leaflets, and also to the patient's condition and life expectancy (Ref. 11).
Current alternatives for HV replacements are mechanical and biological (xenogeneic and allogeneic) implants (strategy A in Figure 3 ). 
Mechanical implants
Bioprosthetic valves
The bioprosthetic valves can be obtained from animal (xenografts) or human origin (autografts and allografts/ homografts). Compared with their mechanical counterparts, bioprostheses are affected by structural dysfunction due to tissue degeneration, so they need to be replaced within 10-15 years. 
Human homografts and the importance of heart valve tissue banking
Since the last century, thousands of heart valve homografts (especially aortic and pulmonary) have been used in reconstructive cardiac surgery and tissue replacement (Ref. 16, 44, 55, 56) . One of the main differences between cardiac valve homografts and other tissues for transplantation (e.g. bone) is that the valve conduits need to perform at its best immediately after surgery. Additionally, the clinical outcome of an homograft can be conditioned by the physiologic process of inflammation, the biomechanical stress, the immune response and other molecular events.
Once the tissue has been transplanted, the analysis of factors which could play a significant role in its deterioration also remains as controversial issue. 
Tissue-engineered heart valves
Heart valve tissue engineering represent a promising strategy to create prostheses with similar functional and biomechanical properties to native heart valves (Ref. 84). They should be able to withstand the repetitive changes in shape, dimensions, and stress generated by the opening and closing cycles they are subjected to during cardiac beating (Ref. 85 Figure 3 (options A, B, and C). Additionally, the progresses reached in TE through in vitro studies, preclinical studies, and clinical trials are summarized in Tables 2, 3 , and 4, respectively.
Challenge 1: Selecting biomaterials for scaffolds
The success of the TEHV strongly depends on the biocompatible materials selected to construct the scaffold and the resulting physicochemical properties (Ref. 88). The scaffold is the threedimensional (3D) structure that allows cells to adhere, generate ECM, grow, migrate, and also differentiate. Some crucial processes that can
On-going clinical treatments and future possibilities in heart valve tissue engineering (HVTE)
guarantee the full integration of the implant into the heart.
The scaffolds of TEHVs face important challenges in terms of integrity, mechanical strength, calcification resistance, and thrombosis risk; but even more important, they must be prepared to deal with the cardiac environment conditions immediately upon implantation (Ref. 89). As shown in Figure 3 , there are mainly two types of scaffold for HVTE: acellular native valves and artificially engineered scaffolds; in case of the latter, its constituents need to be carefully considered, since the aim is to mimic the native valve anatomy and functionality.
Finally, the materials selected must be suitable for different manufacturing processes and reasonably accessible, enabling mass production that caters to the important demand in a shorter time than the currently available (Ref. 90). The main advantages of decellularization are the retention of the original structure as well as many ECM proteins, preservation of the mechanical properties, and a relatively low cost. However, there are serious limitations such as the possibility of disease transmission, or excessively high density and stiffness. Moreover, the porosity is especially low on valves decellularized and treated with crosslinking agents. A failure in the decellularization process has detrimental consequences for patients as shown in the SynerGRaft trial (Ref. 93). However, the necessity of re-seeding or not a valve after decellularization is still the subject of an intense debate. Some authors argue that in vitro recellularization is not a realistic strategy that can be translated into routine clinical practices because of its high financial and time costs (Ref. 94). Indeed, some studies demonstrate that the seeded cells do not survive when the valve is introduced into the patient and that the host's cells may be the origin of the observed repopulation (Ref. 91) . A summary of reported clinical experiences is given in Table 2 . It should be noted that this strategy, which is labelled as B in Figure Although it has been proved that host cells can recolonize the scaffold, a study comparing native heart valves with decellularized and recolonized ones, concluded that the cell types present in the manipulated structures are different from the native ones. This may interfere in the normal function and/or stability of the valve. Additionally, the limited re-endothelization that can be achieved in decellularized matrices can compromise their integration and long term viability. In vivo recellularization studies have stated that pretreatment with host cells can improve scaffold's biocompatibility reducing calcinosis (Ref. 101). Therefore, a short-term incubation of the scaffold with cells and/or unprocessed cell preparations from the patient seems to help in both the recellularization and cell survival outcomes (Ref. 
Decellularized cardiac valve scaffolds from allogeneic/xenogeneic sources
Artificially engineered scaffolds
The alternative to decellularization seems to be de novo construction of natural or synthetic scaffolds using biocompatible and biodegradable materials. The ideal artificial scaffold should take into account the anisotropy and heterogeneity of native valves. Two types of scaffold for TEHVs are usually created: fibrous and porous. The classical method for manufacture porous scaffolds has been to mould thermoplastic biomaterials into 3D structures (Ref. 104, 105, 106 112) . Nevertheless, the use of cytotoxic wavelengths and the necessity of additional coating to improve cell adhesion means that further research in this field is imperative in order to find more realistic alternatives.
A. Fabricated scaffolds from synthetic materials
The production of synthetic scaffolds can be easily controlled allowing reproducibility, standardization, and stable properties. Theoretically, they are designed to create bioabsorbable matrices that act as transitional platforms until the seeded cells replace the synthetic polymers by natural ECM proteins. The synthetic scaffolds can be produced cost-effectively with enough strength and stiffness, and showing important advantages such as low thrombogenicity, and immunogenicity. However, their structural complexity, shape and elastomeric properties are still far from decellularized valves or native tissue. PHA seems to be the biomaterial family most often used for creating highly porous solid scaffolds when preparing scaffolds for 3-leaflet heart valves. On the contrary, most of fibrous scaffolds seem to be produced from PGA using mechanical drawing or electrospinning. PHA shows a wide range of mechanical and thermal properties, but, above all, it stands out because it may be manipulated using a wide range of processing techniques (Ref. 127, 128) . Their use improves the biocompatibility of the scaffold, and provides better cell adhesion, growth and differentiation. Therefore, as a natural evolution to the use of synthetic valves, the scaffolds can also be constructed with biological ECM proteins. A summary of representative in vitro studies using different biomaterials and manufacturing methods is given in Table 3 . Note that many of the in vitro studies highlight the resulting constructions are characterized by weak matrices and poor mechanical properties. This and the fact that it is hard to obtain sufficient amount of the proteins required, indicate that alternative sources, such as cultured human cells, should be found to avoid the risk of zoonosis from animal components (Ref. 133) . It is certainly clear that human collagen or fibrin-based valves are far from being feasible.
B. Fabricated scaffolds from natural materials
Other approaches for HVTE
Among other AM approaches, 3D printing is one of the most promising technologies that would allow the construction of fully customized TEHVs with accurate geometry, and controlled properties designed to suit patients' specific needs. Enhanced levels of complexity might be achieved by the inclusion of various materials and cell types simultaneously at each step of the manufacturing process (Ref. 134) . A proof of concept has already been performed by Butcher's group using the opensource 3D printer Fab@home (Ref. 112, 135) . In general, this approach uses cell encapsulated in synthetic and/or natural hydrogels to generate heterogeneous and multi-scaled biological constructions. For instance, inkjet printing, which can fuse scaffold construction and recellularization into one step, allows the addition of different cell types during valve generation providing a better integration of the components (Ref. 136). All of these are still early stage technologies that promise less labour-intensive fabrication of patient-specific TEHVs.
Challenge 2: Cell candidates for TEHVs
In all TE systems, the cells are the commanders of regeneration, while the rest of the components act as a biological support (Ref. 137). For this reason, a proper selection of the cell types is the key part to succeed. An ideal candidate must satisfy the following criteria. First, cells should be in the appropriate differentiation status for re-establishing the desired functions, supporting mechanical loads, and synthesizing ECM proteins (Ref. 12 ). Second, they should be immune-compatible. So, the best scenario would be the use of autologous cells because native heart valve cells have the most suitable phenotype, and the potential to synthesize ECM and remodel the bioscaffold (Ref. 138); however, their low availability, and the isolation and maintenance difficulties associated with them are serious impediments.
In this section, we present recent progress in the search for cell candidates as well as some conclusions derived from the studies performed. The cell types selected should be able to produce all cell populations in the heart valve. To cover these issues we include in this paper the advances made in HVTE using different cell types such embryonic stem cells (ESCs), induced pluripotent stem cells (IPSs) and even foetal cells, which represent the main candidate to generate prenatal constructs (Figure 3 ).
Adult Stem cells A. Vascular endothelial cells
They play an important role in valvular function, reducing the risk of coagulation and preventing inflammatory complications. If they are maintained in static culture, the vascular ECs share some similarities with VECs but under steady flow, as we mentioned above, the vascular ECs align perpendicularly to flow direction as vascular smooth muscle cells (SMCs) do (Butcher, 2004 #390 In some cases, those works have also get ahead towards in vivo studies using animal models. The potential of EPCs in TEHV has been tested in few in vitro (Table 2 ) and in vivo studies with encouraging results. A summary of some of the most representative pre-clinical investigations involving different HVTE strategies is given in Table 3 . Coating a PGA scaffold with P4HB was found to improve EPC adhesion (Ref. 115, 158) , similarly, the generation of a heparin/VEGF or chitosan/VEGF multilayer film increased EPC proliferation, adhesion, and migration in decellularized porcine aortic valves (Ref. 99, 100).
B. Endothelial progenitor cells
Their feasibility has also been tested in vivo through a clinical study performed by Cebotari et al. (Ref. 161) . A three and a half year follow-up on two paediatric patients who underwent surgical implantation of human pulmonary valves incubated with peripheral mononuclear cells containing EPCs showed some remarkable findings: Both patient's valves had significantly increased in size as the patients matured without any sign of valvular degradation, and only mild regurgitation was observed. Nevertheless, the exact role of the EPCs in this improvement remained unclear. The ASCs have shown a great potential in the preliminary studies in vitro. When their behaviour in PGA/PH4B scaffolds is compared with human BMSCs or VICs, they showed higher elastin, collagen, and GAG production; they also have a higher migration rate and are more uniformly distributed within the scaffold, which is thought to be due to their higher expression of α-SM actin (Ref. 162). Further experiments in order to optimize their final differentiation to adapt them to the cellular requirements must be address to test the feasibility of this promising source of cells.
C. Mesenchymal stem cells from bone marrow
Because VICs have an intermediate endothelialmesenchymal behaviour and phenotype, mesenchymal stem cells (MSCs) are also being widely studied. These cells can be expanded easily in vitro, differentiate into several cell lineages, produce and organise ECM in a very similar way to native heart valve cells (Ref. 162), and can also respond to mechanical stimuli, adapting their morphology, marker expression, protein production, and migration (Ref. 163). Moreover, they also have important immunomodulatory properties (Ref. 164). In the two following sections we detail the most important sources of MSCs and their propertiesfunctional recuperation (longer than 4 months)(Ref. 86). Similar experiments using neonatal BMSCs also concluded that the construct diameter remained unaltered after 20 weeks, although pulmonary regurgitation was detected after 6 weeks due to the decrease in the cusp dimension (Ref. 124). The process of BMSCs differentiation towards a VIC-like phenotype has been addressed from various perspectives. The classical epigenetic stimulation has been conducted with vascular endothelial growth factor (VEGF) and transforming growth factor β1 and β2 (TGFβ1, TGFβ2) (Ref. 171). Apart from these two, it has been also tested the vector-induced expression of the fibroblast growth factor-inducible 14 (Fn14) differentiation factor (Ref. 174) and other functional proteins such as eNOS (Ref. 169). Nevertheless, exposure to mechanical stress is essential for their full differentiation toward ECs: after flow-rate stimulation BMSCs showed better integration
Prenatal extraembryonic cell sources
In addition to the abovementioned adult SCs, foetal and extra-foetal tissues represent additional sources of SCs. As we mentioned above the paediatric problem is one of the challenges in cardiovascular treatments. The finding of autologous, viable and growing replacements such as TEHVs would reduce the insurmountable therapeutic limitations in the treatment of children carrying congenital heart diseases. The majority of these cardiac defects can be detected around week 20 of pregnancy. Autologous stem/progenitor cells can be isolated from several of the foetal annex structures, without damage or compromise the foetus itself. The relevant cells prenatally harvested are amniotic fluid-derived cells (AFDCs), chorionic villi-derived mesenchymal progenitor cells, and umbilical cord blood (UCB) derived EPCs (Ref. 102). The cells obtained show a higher expansion rate and plasticity to produce a wider variety of cell lineages that can be used for autologous TEHV implants at birth or prenatally.
A. Amniotic fluid-derived cells
Amniotic fluid represents an attractive foetal cell source for the concept of paediatric heart valve tissue engineering since it renders possible prenatal access to foetal cells from all three germ layers via a low-risk procedure (Ref. 150 (Ref. 193, 194) . The feasibility of generating living autologous heart valve leaflets in vitro using human amniotic fluid as a single cell source and also by combination of mesenchymal ADCs with amniotic fluid endothelial precursors has been already attempted (Ref. 195) . This research group also demonstrated the in vivo functionality of autologous AFDCs seeded over biodegradable PGA/P4HB scaffolds and transplanted into sheep fetuses before birth (Ref. 196, 197) .
B. Chorionic villi-derived mesenchymal stem cells
The chorion is one of the membranes that conform the human placenta. The greatest roadblock in these initial studies is the overgrowth of maternal cells, that sometimes are also present in the samples a fact that needs to be avoided in the future., chorionic villi samples also contain foetal capillary endothelial cells, which might also be isolated using cell sorting techniques as part of future therapeutic attempts (Ref. 198 ).
C. Umbilical cord blood derived-endothelial progenitor cells
The umbilical cord is a common source of hematopoietic cells, but it may also become an invaluable source of non-hematopoietic SCs, the UCB-derived EPCs. iPSCs are generated by inducing the expression of certain stemness genes in adult differentiated cells extracted from patient's own tissues (Ref. 204) . Recently, they have been proven to be capable of repopulating decellularized mouse heart valves (Ref. 205 ), but the generation of functional TEHVs requires further research, especially in controlling cell differentiation. Although the promise of revolutionary improvements in TE, patient-derived iPSCs are still far from clinical practice; they still represent valuable models to study the origin and development of heart valves.
Conclusion and future outlook
The ideal replacement for heart valves would be an alive and immune-compatible implant containing both endothelial and interstitial cells. These cells must produce and remodel the appropriate ECM to address the growth of the graft in accordance with patient's development. The structure of the TEHVs also needs to be fully functional in terms of hemodynamics and biomechanics immediately upon implantation. For now, none of the available solutions in the market accomplish all these requirements.
Mechanical and biological heart valve prosthesis, as mentioned before, continue as the gold standard in surgical replacement procedures, saving millions of lives. However, both lack the properties of living replacements, with the subsequent inability to regenerate and growth. Additionally, mechanical substitutes also carry with them the side effects of anticoagulation drugs. For the moment, homografts and autografts appear to be the best clinical solution. But considering the evolution of modern society, the age of potential homograft donors is constantly increasing because of the aging of the population in general. This suggests that the availability and quality of the donated organs is decreasing. In addition, the heterogeneous cellular composition of native valves indicates that different cell types should be seeded sequentially or simultaneously to reach the most realistic approach to create TEHVs. Innovative advances such as noninvasive imaging systems to monitoring the tissue regeneration or new flexible manufacturing techniques might be introduce in the equation. For all these reasons we firmly believe the best solution to this important social-sanitary problem is yet to come and probably remains hidden in the laboratory.
We have come a long way since Vacanti attempted the creation of a TEHV almost 20 years ago. The progress is remarkable in many senses, especially due to recent advances on SC and biodegradable scaffolds, but few advances in HVTE have reached clinical stage. This can be due to several reasons, often interrelated; in our opinion, and considering the heterogeneous cellular composition of the native valves, the complexity of constructions needs to be drastically increased. Current scaffolds also fail to provide the proper properties in terms of morphology and biomechanics that promising artificial implants require to be capable of addressing current limitations of donor supply shortage. They also need to be manufactured with a composition and internal structure that makes them able to convey and release growth factors required in the cell niche of TEHVs.
Additional effort must be given to assess the safety and efficacy of TEHVs before they will be ready to clinical routine. First, based on accumulated experience, it is mandatory to standardize and optimize the combinations of different candidate cells, biomaterials and culture conditions, establishing the criteria to correlate in vitro outcomes with in vivo experiments. Deeper in vitro characterization of TEHVs at structural and functional levels should be carried out, and additional strategies and criteria are required to this end. Current in vivo models must be replaced by others that better reflects the properties of human cardiac valves. Until now, the ovine model is routinely employed in preclinical studies, but the hemodynamic characteristics of sheep valve significantly differ from human ones. Therefore this might not be a good model to perform preclinical studies.
Finally, it would be very beneficial for the field to join efforts and obtain global conclusions about the on-going research on HVTE. In this sense, the creation of databases for lending the standardization of in vitro TEHV results should be an interesting strategy. Develop an strict preclinical (in vitro and in vivo) quality control criteria before attempt clinical trials is also mandatory. Finally, enormous research effort will be also necessary to analyse and predict the individual response among patients.
In our opinion, progress in the field will require laboratories with advanced technologies and novel manufacturing strategies and multidisciplinary teams in which close collaboration between developmental biologists, surgeons, engineers, polymer chemists and pharmacists will provide new insights. Without any doubt, we can asses that it will be sometime before we will find the perfect match able to mend a broken heart.
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